Passage Bio, Inc. (PASG)
NASDAQ$0.4036+0.01 (2.55%)
Market Cap
$24.36M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
177 of 924
Rank in Industry
110 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PASG Insider Trading Activity
PASG Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $525,558 | 4 | 19 |
Sells | $689,364 | 17 | 81 |
Related Transactions
| Lynx1 Capital Management LP | 10 percent owner | 4 | $525,558 | 0 | $0 | $525,558 |
| Borthwick Kathleen | CFO | 0 | $0 | 1 | $1,686 | $-1,686 |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 | $0 | 16 | $687,678 | $-687,678 |
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the …
Insider Activity of Passage Bio, Inc.
Over the last 12 months, insiders at Passage Bio, Inc. have bought $525,558 and sold $689,364 worth of Passage Bio, Inc. stock.
On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $838,517 and sold $300,185 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $525,558.
The last purchase of 373,645 shares for transaction amount of $241,038 was made by Lynx1 Capital Management LP (10 percent owner) on 2024‑12‑27.
List of Insider Buy and Sell Transactions, Passage Bio, Inc.
| 2025-02-11 | Sale | Borthwick Kathleen | CFO | 3,183 0.0048% | $0.53 | $1,686 | -2.18% | |
| 2025-01-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 79,024 0.1279% | $0.60 | $47,414 | -6.66% | |
| 2025-01-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 17,986 0.0293% | $0.64 | $11,511 | -12.49% | |
| 2025-01-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 126,209 0.2013% | $0.66 | $83,298 | -16.32% | |
| 2025-01-08 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 75,007 0.127% | $0.68 | $51,005 | -14.83% | |
| 2025-01-07 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 52,536 0.0851% | $0.71 | $37,301 | -19.19% | |
| 2025-01-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 19,481 0.0315% | $0.77 | $15,000 | -25.38% | |
| 2024-12-27 | Lynx1 Capital Management LP | 10 percent owner | 373,645 0.6097% | $0.65 | $241,038 | -12.49% | ||
| 2024-12-20 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 230,321 0.3317% | $0.60 | $138,193 | -12.20% | |
| 2024-12-11 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 80 0.0001% | $0.80 | $64 | -22.81% | |
| 2024-12-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 8,015 0.013% | $0.80 | $6,412 | -25.79% | |
| 2024-12-09 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 54,181 0.0924% | $0.84 | $45,512 | -26.11% | |
| 2024-12-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 20,903 0.0352% | $0.82 | $17,140 | -23.42% | |
| 2024-12-04 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 76,200 0.1269% | $0.79 | $60,198 | -20.30% | |
| 2024-11-27 | Lynx1 Capital Management LP | 10 percent owner | 29,300 0.0467% | $0.67 | $19,663 | -10.06% | ||
| 2024-11-26 | Lynx1 Capital Management LP | 10 percent owner | 167,055 0.2621% | $0.71 | $118,191 | -20.11% | ||
| 2024-11-25 | Lynx1 Capital Management LP | 10 percent owner | 259,998 0.3493% | $0.56 | $146,665 | -3.38% | ||
| 2024-09-19 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,300 0.0645% | $0.71 | $27,903 | -13.64% | |
| 2024-09-18 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 25,631 0.0432% | $0.73 | $18,711 | -13.66% | |
| 2024-09-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 111,400 0.181% | $0.73 | $81,322 | -16.67% |
Total: 64
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Lynx1 Capital Management LP | 10 percent owner | 9256953 14.8949% | $3.63M | 4 | 0 | |
| ORBIMED ADVISORS LLC | 10 percent owner | 7034626 11.3191% | $2.76M | 10 | 16 | <0.0001% |
| OrbiMed Capital GP VII LLC | 6537923 10.5199% | $2.56M | 1 | 0 | <0.0001% | |
| Heron Patrick J | 5009219 8.0601% | $1.96M | 1 | 0 | <0.0001% | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 5009219 8.0601% | $1.96M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$53,490,060 | 55 | 19.35% | $27.74M | |
$1,363,112 | 33 | 15.03% | $23.32M | |
Passage Bio, Inc. (PASG) | $94,084,626 | 29 | -21.08% | $24.36M |
$1,295,471 | 17 | 21.79% | $24.53M | |
$25,487,383 | 15 | -4.37% | $24.05M |
PASG Institutional Investors: Active Positions
| Increased Positions | 20 | +37.04% | 2M | +5.32% |
| Decreased Positions | 19 | -35.19% | 3M | -8% |
| New Positions | 10 | New | 66,742 | New |
| Sold Out Positions | 9 | Sold Out | 569,507 | Sold Out |
| Total Postitions | 55 | +1.85% | 38M | -2.68% |
PASG Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Lynx1 Capital Management Lp | $4,795.00 | 14.93% | 9.26M | +829,998 | +9.85% | 2024-12-31 |
| Orbimed Advisors Llc | $3,836.00 | 11.94% | 7.4M | -2M | -24.62% | 2024-12-31 |
| Vestal Point Capital, Lp | $3,160.00 | 9.84% | 6.1M | 0 | 0% | 2024-12-31 |
| New Leaf Venture Partners, L.L.C. | $1,294.00 | 4.03% | 2.5M | 0 | 0% | 2024-12-31 |
| Erste Asset Management Gmbh | $1,272.00 | 3.96% | 2.46M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,073.00 | 3.34% | 2.07M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $777.00 | 2.42% | 1.5M | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $716.00 | 2.23% | 1.38M | -11,370 | -0.82% | 2024-12-31 |
| Acadian Asset Management Llc | $488.00 | 1.52% | 942,900 | -18,371 | -1.91% | 2024-12-31 |
| Morgan Stanley | $421.00 | 1.31% | 812,442 | +799,000 | +5,944.06% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.